{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:06:33Z","timestamp":1785391593887,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Cannabinoids are approved for spasticity and pain in multiple sclerosis (MS). In 2017 the prevalence of current users in the Italian general population was 10.2%, while data on Italian MS patients are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From March 2022 to February 2023, we conducted a multicenter, cross-sectional study. Adult MS patients completed an anonymous online survey. The primary outcome was the estimated prevalence of unprescribed cannabis current use. Cannabis use patterns and associations with clinical and socio-demographical variables were investigated. The binomial method was used to estimate 95% confidence interval (95% CI) for primary outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>5620 patients were invited and 2024 (36.0%) were included (mean age 45.2\u00a0years, females 64.5%). Relapsing\u00a0remitting form was the most frequent (77.3%). Median expanded disability status scale (EDSS) was 2.0. The proportion of current users was 15.5% (95% CI 13.9\u201317.1) and 36.4% of them disclosed to their physician their unprescribed cannabis use. 15.0% patients were former users while 69.5% never used cannabis. Current users more frequently reported a medical use (i.e., current medical users) compared to former users (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). 41.1% of never users would use cannabis if it was legal. Young age, being male, and a free marital status were associated with current use. Current medical users had higher disability, spasticity and pain, reduced quality of life, concomitant neurological\/psychiatric drugs and analgesics use. Unprescribed cannabis appeared relatively safe, with limited addiction risk, and reported clinical benefits, including concomitant medications reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Unprescribed cannabis use is common in patients with MS in Italy, with observed prevalence seemingly superior to the general population, often intended for medical use and without the disclosure to the treating physician, although with potential clinical benefits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12472-4","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:32:14Z","timestamp":1717731134000},"page":"7186-7205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-9445","authenticated-orcid":false,"given":"Riccardo","family":"Giossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mercenari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giuseppe","family":"Antozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Confalonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano Giuseppe","family":"Crisafulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Tomas Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Zaffira","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Barril\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ronzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Grobberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gustavsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Torri Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"12472_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378:169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"key":"12472_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/JPR.S192174","volume":"12","author":"MA Ueberall","year":"2019","unstructured":"Ueberall MA, Essner U, Mueller-Schwefe GH (2019) Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res 12:1577\u20131604. https:\/\/doi.org\/10.2147\/JPR.S192174","journal-title":"J Pain Res"},{"key":"12472_CR3","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666230727094431","author":"D Kleiner","year":"2023","unstructured":"Kleiner D, Horv\u00e1th IL, Bunduc S et al (2023) Nabiximols is efficient as add-on treatment for patients with multiple sclerosis spasticity refractory to standard treatment: a systematic review and meta-analysis of randomised clinical trials. Curr Neuropharmacol. https:\/\/doi.org\/10.2174\/1570159X21666230727094431","journal-title":"Curr Neuropharmacol"},{"key":"12472_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104745","volume":"75","author":"J Nicholas","year":"2023","unstructured":"Nicholas J, Lublin F, Klineova S et al (2023) Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials. Mult Scler Relat Disord 75:104745. https:\/\/doi.org\/10.1016\/j.msard.2023.104745","journal-title":"Mult Scler Relat Disord"},{"key":"12472_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11910-018-0859-x","volume":"18","author":"J Rice","year":"2018","unstructured":"Rice J, Cameron M (2018) Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep 18:50. https:\/\/doi.org\/10.1007\/s11910-018-0859-x","journal-title":"Curr Neurol Neurosci Rep"},{"key":"12472_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327\u2013360. https:\/\/doi.org\/10.2165\/00003088-200342040-00003","journal-title":"Clin Pharmacokinet"},{"key":"12472_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215. https:\/\/doi.org\/10.1038\/sj.bjp.0707442","journal-title":"Br J Pharmacol"},{"key":"12472_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228870","author":"J Mlost","year":"2020","unstructured":"Mlost J, Bryk M, Starowicz K (2020) Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21228870","journal-title":"Int J Mol Sci"},{"key":"12472_CR9","unstructured":"No Title. https:\/\/www.salute.gov.it\/portale\/medicinaliStupefacenti\/dettaglioContenutiMedicinaliStupefacenti.jsp?lingua=italiano&id=4587&area=sostanzeStupefacenti&menu=organismo. Accessed 29 Sept 2023"},{"key":"12472_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/1352458506070947","volume":"12","author":"MS Chong","year":"2006","unstructured":"Chong MS, Wolff K, Wise K et al (2006) Cannabis use in patients with multiple sclerosis. Mult Scler 12:646\u2013651. https:\/\/doi.org\/10.1177\/1352458506070947","journal-title":"Mult Scler"},{"key":"12472_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ctim.2017.07.002","volume":"33","author":"JH Kindred","year":"2017","unstructured":"Kindred JH, Li K, Ketelhut NB et al (2017) Cannabis use in people with Parkinson\u2019s disease and multiple sclerosis: a web-based investigation. Complement Ther Med 33:99\u2013104. https:\/\/doi.org\/10.1016\/j.ctim.2017.07.002","journal-title":"Complement Ther Med"},{"key":"12472_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1017\/S0317167100002584","volume":"30","author":"SA Page","year":"2003","unstructured":"Page SA, Verhoef MJ, Stebbins RA et al (2003) Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 30:201\u2013205. https:\/\/doi.org\/10.1017\/S0317167100002584","journal-title":"Can J Neurol Sci"},{"key":"12472_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103172","volume":"55","author":"J Rice","year":"2021","unstructured":"Rice J, Hildebrand A, Spain R et al (2021) A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington. Mult Scler Relat Disord 55:103172. https:\/\/doi.org\/10.1016\/j.msard.2021.103172","journal-title":"Mult Scler Relat Disord"},{"key":"12472_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.msard.2019.05.008","volume":"33","author":"S Gustavsen","year":"2019","unstructured":"Gustavsen S, S\u00f8ndergaard HB, Andresen SR et al (2019) Illegal cannabis use is common among Danes with multiple sclerosis. Mult Scler Relat Disord 33:5\u201312. https:\/\/doi.org\/10.1016\/j.msard.2019.05.008","journal-title":"Mult Scler Relat Disord"},{"key":"12472_CR15","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2018) European monitoring centre for drugs and drug addiction: European Drug Report 2018: trends and developments"},{"key":"12472_CR16","unstructured":"Relazione sui dati relativi allo stato delle tossicodipendenze in Italia (Anno 2017). https:\/\/www.politicheantidroga.gov.it\/media\/2445\/339911.pdf"},{"key":"12472_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10072-016-2519-8","volume":"37","author":"A Loraschi","year":"2016","unstructured":"Loraschi A, Bellantonio P, Bortolon F et al (2016) Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurol Sci 37:613\u2013622. https:\/\/doi.org\/10.1007\/s10072-016-2519-8","journal-title":"Neurol Sci"},{"key":"12472_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1177\/1352458518774935","volume":"25","author":"R Rosato","year":"2019","unstructured":"Rosato R, Testa S, Bertolotto A et al (2019) eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Mult Scler 25:856\u2013866. https:\/\/doi.org\/10.1177\/1352458518774935","journal-title":"Mult Scler"},{"key":"12472_CR19","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.2147\/NDT.S184260","volume":"14","author":"JL Pais-Ribeiro","year":"2018","unstructured":"Pais-Ribeiro JL, Martins da Silva A, Vilhena E et al (2018) The hospital anxiety and depression scale, in patients with multiple sclerosis. Neuropsychiatr Dis Treat 14:3193\u20133197. https:\/\/doi.org\/10.2147\/NDT.S184260","journal-title":"Neuropsychiatr Dis Treat"},{"key":"12472_CR20","unstructured":"Relazione annuale al Parlamento sul fenomeno delle tossicodipendenze in Italia. https:\/\/www.politicheantidroga.gov.it\/media\/ix0b0esf\/relazione-al-parlamento-2023.pdf"},{"key":"12472_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102261","volume":"44","author":"M Hanna","year":"2020","unstructured":"Hanna M, Strober LB (2020) Anxiety and depression in multiple sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord 44:102261. https:\/\/doi.org\/10.1016\/j.msard.2020.102261","journal-title":"Mult Scler Relat Disord"},{"key":"12472_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hup.1048","volume":"24","author":"JA Crippa","year":"2009","unstructured":"Crippa JA, Zuardi AW, Mart\u00edn-Santos R et al (2009) Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24:515\u2013523. https:\/\/doi.org\/10.1002\/hup.1048","journal-title":"Hum Psychopharmacol"},{"key":"12472_CR23","unstructured":"Global Drug Survey (GDS) 2021 key findings report. https:\/\/www.globaldrugsurvey.com\/wp-content\/uploads\/2021\/12\/Report2021_global.pdf"}],"updated-by":[{"DOI":"10.1007\/s00415-024-12560-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12472-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12472-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12472-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T09:04:46Z","timestamp":1731488686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12472-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["12472"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12472-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-024-12560-5","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-024-12560-5","URL":"https:\/\/doi.org\/10.1007\/s00415-024-12560-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. R. Giossi received support for congress participation from Mylan and acted as a consultant for Daiichi-Sankyo, outside this work. Prof. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Horizon, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Horizon, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Horizon, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Dr. C. Zanetta received compensation for speaking activities, and\/or consulting services, from Alexion, Astrazeneca, Biogen, Bristol-Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi. Dr. C. Antozzi\u00a0received funding for traveling from Teva, Merck and Biogen. Dr. L. Brambilla received honoraria for speaking from Novartis, Roche, Horizon, and for traveling from Sanofi-Genzyme, Merck-Serono, Novartis, Horizon and Roche; she acted as an Advisory Board member of Sanofi-Genzyme, Novartis and Merck-Serono and she is\u00a0involved as principal investigator in clinical trials for\u00a0Roche and Merck-Serono.\u00a0Dr. P. Confalonieri\u00a0has received honoraria for speaking or consultation fees from Novartis, Bristol Myers and Biogen, has received funding for travel to attend scientific events or speaker honoraria from Merck-Serono, Biogen Idec, Mylan and Roche. He has also received institutional research support from Merk-Serono, Novartis and Roche.\u00a0He is also principal investigator in clinical trials for Novartis and Roche. Dr. S.G. Crisafulli received support for congress participation from Mylan, Merck-Serono, Novartis. He acted as an Advisory Board member for Novartis. Dr. P. Annovazzi received honoraria for lecturing and participation in advisory boards, and\/or travel expenses for attending congresses and meetings from Alexion, Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and Viatris. Dr. C. Barril\u00e0 participated in improvements groups for Biogen, Sanofi, Novartis, and Merck. Dr. M. Ronzoni received honoraria for congress participation and\/or advisory board from Alexion, Almirall, Biogen, Bristol Meyers Squibb, Horizon, Genzyme, Merck, Novartis, Roche, Sanofi, and Teva. Dr. S. Gustavsen has received support for congress participation from Merck and Sanofi. Dr. V. Torri Clerici\u00a0acted as an Advisory Board member of Biogen\u00a0Idec and Novartis, and received funding for travelling and honoraria for speaking or writing from Teva, Novartis, Genzyme, Almirall. She received support for research project by Almirall.\u00a0Other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}